Analysts forecast that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will report sales of $97.49 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Ironwood Pharmaceuticals’ earnings, with estimates ranging from $92.15 million to $103.91 million. Ironwood Pharmaceuticals posted sales of $94.21 million during the same quarter last year, which would indicate a positive year over year growth rate of 3.5%. The firm is scheduled to report its next earnings report on Thursday, February 21st.

On average, analysts expect that Ironwood Pharmaceuticals will report full year sales of $321.64 million for the current fiscal year, with estimates ranging from $308.10 million to $342.30 million. For the next fiscal year, analysts expect that the firm will report sales of $419.94 million, with estimates ranging from $341.31 million to $530.18 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.24). The business had revenue of $68.69 million during the quarter, compared to analysts’ expectations of $93.48 million. During the same quarter last year, the company earned ($0.18) earnings per share. Ironwood Pharmaceuticals’s revenue for the quarter was down 20.9% on a year-over-year basis.

Several analysts have issued reports on IRWD shares. Wells Fargo & Co set a $19.00 price target on Ironwood Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, October 31st. Morgan Stanley set a $11.00 price target on Ironwood Pharmaceuticals and gave the company a “sell” rating in a research note on Wednesday. ValuEngine downgraded Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 31st. HC Wainwright set a $13.00 target price on Ironwood Pharmaceuticals and gave the company a “sell” rating in a research report on Tuesday, August 7th. Finally, BTIG Research set a $17.00 target price on Ironwood Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $17.35.

In related news, insider Mark G. Currie sold 130,000 shares of Ironwood Pharmaceuticals stock in a transaction dated Thursday, August 23rd. The stock was sold at an average price of $18.45, for a total value of $2,398,500.00. Following the sale, the insider now owns 791,666 shares of the company’s stock, valued at $14,606,237.70. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mark G. Currie sold 116,651 shares of Ironwood Pharmaceuticals stock in a transaction dated Friday, October 5th. The shares were sold at an average price of $17.53, for a total value of $2,044,892.03. Following the completion of the sale, the insider now directly owns 70,680 shares in the company, valued at approximately $1,239,020.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 248,339 shares of company stock worth $4,475,466. 7.63% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. OppenheimerFunds Inc. grew its holdings in Ironwood Pharmaceuticals by 11.1% during the second quarter. OppenheimerFunds Inc. now owns 2,872,640 shares of the biotechnology company’s stock worth $54,925,000 after purchasing an additional 286,590 shares during the period. Aperio Group LLC grew its holdings in Ironwood Pharmaceuticals by 34.2% during the second quarter. Aperio Group LLC now owns 21,185 shares of the biotechnology company’s stock worth $405,000 after purchasing an additional 5,404 shares during the period. Meeder Asset Management Inc. bought a new position in Ironwood Pharmaceuticals during the second quarter worth about $186,000. Schwab Charles Investment Management Inc. grew its holdings in Ironwood Pharmaceuticals by 6.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 722,555 shares of the biotechnology company’s stock worth $13,816,000 after purchasing an additional 44,157 shares during the period. Finally, Public Employees Retirement System of Ohio grew its holdings in Ironwood Pharmaceuticals by 11.3% during the second quarter. Public Employees Retirement System of Ohio now owns 120,370 shares of the biotechnology company’s stock worth $2,301,000 after purchasing an additional 12,175 shares during the period. Institutional investors and hedge funds own 97.29% of the company’s stock.

Shares of IRWD traded down $0.20 during midday trading on Wednesday, hitting $11.88. The stock had a trading volume of 1,677,504 shares, compared to its average volume of 1,784,796. Ironwood Pharmaceuticals has a twelve month low of $11.62 and a twelve month high of $21.20. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -12.77 and a beta of 1.33.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.

See Also: What is Liquidity?

Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.